	US 11,814,651 B2
	Cell and utilization thereof
Hideyuki Saya, Tokyo (JP); Yoshimi Arima, Tokyo (JP); Takashi Semba, Tokyo (JP); and Akiyoshi Kasuga, Tokyo (JP)
Assigned to FUJITA ACADEMY, Aichi (JP)
Appl. No. 16/490,786
Filed by FUJITA ACADEMY, Aichi (JP)
PCT Filed Mar. 7, 2018, PCT No. PCT/JP2018/008735 § 371(c)(1), (2) Date Sep. 3, 2019, PCT Pub. No. WO2018/164174, PCT Pub. Date Sep. 13, 2018.
Claims priority of application No. 2017-042659 (JP), filed on Mar. 7, 2017.
Prior Publication US 2020/0017834 A1, Jan. 16, 2020
Int. Cl. C12N 5/071 (2010.01); A01K 67/027 (2006.01); A61K 49/00 (2006.01); C12N 5/095 (2010.01); C12Q 1/02 (2006.01)

CPC C12N 5/0689 (2013.01) [A01K 67/027 (2013.01); A61K 49/0008 (2013.01); C12N 5/0695 (2013.01); C12Q 1/025 (2013.01); A01K 2207/12 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); C12N 2500/30 (2013.01); C12N 2500/90 (2013.01); C12N 2501/11 (2013.01); C12N 2501/117 (2013.01); C12N 2506/27 (2013.01); C12N 2513/00 (2013.01)]

8 Claims

1. A cell population of epithelial tissue stem cells derived from an adult,

wherein the epithelial tissue stem cells are lung, gall bladder or bile duct epithelial cells and wherein the epithelial tissue stem cells lack at least one tumor suppressor gene and the cell population expresses Epithelial cell adhesion molecule (EpCAM) and Stem cell antigen-1 (Sca-1), and wherein 50% or more of the EpCAM⁺cells in the cell population are Sca-1⁺.